Tags: spms + mbp8298.with.MS

Sort by: Date / Title / URL

1. BioMS Medical initiates enrollment in pivotal U.S. phase III multiple sclerosis trial
   the first patients have been enrolled in MAESTRO-03, its U.S. pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis
   07-06-2007 to clinical trial, drug company, drugs, mbp8298, ms, multiple sclerosis, spms by admin
2. BioMS Medical Announces Lead Investigator In United States Phase III Multiple Sclerosis Trial
   BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce Dr. Clyde E. Markowitz as the lead investigator in the United States for the Company’s pivotal phase III clinical trial of its lead dru
   28-04-2007 to canada, drug company, drugs, mbp8298, multiple sclerosis, spms by admin
3. BioMS Medical initiates follow-on open-label MAESTRO-02 Multiple Sclerosis trial of MBP8298
   BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that it has initiated MAESTRO-02, the open-label follow-on portion to its MAESTRO-01 pivotal phase II/III clinical trial of MBP8298
   05-03-2007 to drug company, drugs, mbp8298, multiple sclerosis, spms, treatment by admin
4. BioMS - Clinical Trial Information for MBP8298
   A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis
   14-08-2006 to clinical trial, drug company, drugs, mbp8298, multiple sclerosis, spms by admin

First / Previous / Next / Last / Page 1 of 1